Emergency Management of Acute Ischemic Stroke The Evolving Roles of Intravenous and Endovascular Therapies

Therapies Thursday, July 18th, 2013

JAMA Neurol: 7/1/13

In 1996, the US Food and Drug Administration approved the use of intravenous recombinant tissue plasminogen activator (rtPA) for the treatment of carefully selected patients with acute ischemic stroke who could receive the medication within 3 hours of onset of symptoms. Since that time, the maximum time window for treatment has been expanded to 4.5 hours. Guidelines are available to provide recommendations and advice for the use of intravenous rtPA.1 As a result, rtPA has revolutionized the care of patients with ischemic stroke; now, patients with stroke may be successfully treated, and outcomes may be improved. Intravenous thrombolysis is now the engine that is driving emergency stroke care. Read more

National Minority Quality Forum Clinical Trial Engagement Network Map Childhood Obesity MapHIV Z-Atlas: Peripheral Arterial Disease Atlas Map Lung Cancer Index Z-Atlas: Chronic Kidney Disease AFIB Index Cardiometabolic Health Aliance Minority Diabetes Coalition U.S. Diabetes Index County Edition U.S. Diabetes Index Research Edition Medicare Index Medicare Index Stroke Edition About The Minority Stroke Working Group Hepatitis C Disease Index Lead Risk Index Map MRSA StrokePAD Minority Index The South Texas Diabetes Initiative Minority Stroke Consortium YouTube NMQF Videos IPAB Action Center National Health Index

© 2011 National Minority Quality Forum, Inc. All Rights Reserved.